Gyre Therapeutics (GYRE) Interest & Investment Income (2010 - 2023)
Gyre Therapeutics (GYRE) posted quarterly Interest & Investment Income of $47000.0 for Q3 2023, down 83.33% year-over-year from $282000.0 in Q3 2022, and down 35.62% quarter-over-quarter from $73000.0 in Q2 2023.
Gyre Therapeutics (GYRE) Interest & Investment Income (2010 - 2023) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Interest & Investment Income for 14 consecutive years, with $47000.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Interest & Investment Income fell 83.33% year-over-year to $47000.0; the TTM figure through Sep 2023 stood at $384000.0 (down 27.95% YoY), while the FY2022 annual figure was $717000.0, up 1938.46% from the prior year.
- Interest & Investment Income slipped to $47000.0 in Q3 2023 per GYRE's latest filing, from $73000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $489000.0 in Q3 2019 and bottomed at -$99000.0 in Q2 2020.
- Historically, Interest & Investment Income has averaged $102222.2 across 5 years, with a median of $70000.0 in 2020.
- Annual changes were most pronounced in 2020 — Interest & Investment Income slumped 325.0% — and 2022, when it surged 3500.0%.
- Gyre Therapeutics' Interest & Investment Income stood at $377000.0 in 2019, then plunged by 117.51% to -$66000.0 in 2020, then surged by 75.76% to -$16000.0 in 2021, then soared by 1150.0% to $168000.0 in 2022, then plunged by 72.02% to $47000.0 in 2023.
- Business Quant data shows GYRE's Interest & Investment Income at $47000.0 in Q3 2023, $73000.0 in Q2 2023, and $96000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 47,000.00 |
| Jun 30, 2023 | 73,000.00 |
| Mar 31, 2023 | 96,000.00 |
| Dec 31, 2022 | 168,000.00 |
| Sep 30, 2022 | 282,000.00 |
| Jun 30, 2022 | 102,000.00 |
| Mar 31, 2022 | 165,000.00 |
| Dec 31, 2021 | -16,000.00 |
| Sep 30, 2021 | -9,000.00 |
| Jun 30, 2021 | -3,000.00 |
| Dec 31, 2020 | -66,000.00 |
| Sep 30, 2020 | 67,000.00 |
| Jun 30, 2020 | -99,000.00 |
| Mar 31, 2020 | 106,000.00 |
| Dec 31, 2019 | 377,000.00 |
| Sep 30, 2019 | 489,000.00 |
| Jun 30, 2019 | 44,000.00 |
| Mar 31, 2019 | 17,000.00 |
| Dec 31, 2018 | 847,000.00 |
| Sep 30, 2018 | 651,000.00 |